blase polite

GI medical oncologist, cancer health policy expert, deadhead, husband and father of 2

[blase polite @BlasePolite]

@agrothey @DocCatenacci @MPishvaian Strongly agree and drives us crazy when metastatic protocols require it. We almost end up dropping for cycle #2. Time to get this incorporated into protocols.

[Richard Schilsky @rschilsky]

TAPUR results for pembro in mCRC with HTMB ⁦@ASCO⁩ #GI20

[Bassam Estfan @DrEstfan]

Updated survival data from the BEACON study. Doublet encorafenib and cetuximab as good as triplet therapy in BRAF mutant mCRC. #GI20

[Thor Halfdanarson @OncoThor]

DART results finally published, congrats! Problem is, I still don't know what patients were enrolled (well diff vs. poorly diff??). Not all G3 NENs are poorly diff NECs and G3 NETs and G3 NECs are different beasts. But there is a signal... :) https://t.co/FUixoKvpei